Gansu Province has successively lowered the price of several "life-saving drugs" involving 14 drug specifications

Since July, our province has successively lowered the prices of many kinds of drugs Up to now, the prices of 14 drug regulations have been lowered by 51.6% It is worth noting that this price reduction was proposed by the enterprise, and Pfizer and Xi'an Janssen became the "protagonists" of price reduction Prior to that, on July 2, Gansu drug procurement platform issued a notice that Pfizer's six products were reduced in price, and Xi'an YANGSEN products (Dake) fell by 51.6% According to the announcement, in order to actively respond to the national tax reform policy, according to the application of enterprises, the online price of the two enterprises' online products will be adjusted Encourage more enterprises to take the initiative to reduce drug prices to benefit the people The price of Dake, a life-saving drug for patients with high-risk myelodysplastic syndrome, was reduced from 10327.22 yuan to 4996 yuan, with a direct cut of 51.6% It is reported that the product is an important anti-tumor drug of Xi'an Janssen Such a "cut back" price directly makes the product a few drugs with the same price or even lower than the domestic generic drugs in the market Coincidentally, Pfizer did not let go of the opportunity of "price for volume" to seize the market, and together with Xi'an Janssen, it actively applied to reduce the supply price of some drugs, of which the largest decline was Cape, with a price adjustment of 10% On July 2, Pfizer lowered the price of six drug specifications in Gansu Province, among which, the price of drolidine (ziprasidone hydrochloride capsule) was adjusted from 135.41 yuan to 130.51 yuan; the price of keputuo (irinotecan hydrochloride injection) 5ml: 0.1g/box was reduced from 2151.23 yuan to 1931.96 yuan; the price of keputuo (irinotecan hydrochloride injection) 2ml: 40mg / box was reduced from 1175.15 yuan to 105 yuan 5.37 yuan; Taige (tegacyclin), commonly known as "tiger element", was reduced from 912.5 yuan to 866.7 yuan; SVO (linezolid injection), an anti infective drug, was reduced from 382.77 yuan to 362.59 yuan; SVO (linezolid tablets) was reduced from 3686.92 yuan to 3474.64 yuan On July 26, Gansu drug purchase platform issued a notice again to adjust the bid price of 7 anti-tumor drugs for Pfizer Investment Co., Ltd to reduce import tariff This time, Pfizer is singing "monologue" The products applied for price reduction include Diflucan, Vivan and SVO, anti-cancer drug sedza, and Wyeth's hemophilia drug Renjie, etc Among them, Vivan (voriconazole tablets) was reduced from 3460.95 yuan to 3271.08 yuan; Vivan (voriconazole for injection) was reduced from 1019.42 yuan to 962.56 yuan; Dafukang (fluconazole sodium chloride injection) was reduced from 208.08 yuan to 196.72 yuan; Ren Jie (recombinant human coagulation factor VIII for injection) was reduced from 1832 yuan to 1770.75 yuan; ansutai (paclitaxel) was reduced from 854.78 yuan to 805.03 yuan Yuan; 0.1g/bottle of sidesa (cytarabine for injection) was decreased from 44.06 yuan to 39.95 yuan; 500 mg / bottle of sidesa (cytarabine for injection) was decreased from 162.144 yuan to 153.44 yuan So, when can patients enjoy the dividend of drug price reduction? On July 26, the reporter learned from several top three hospitals in provincial cities that at present, patients can't feel the change of terminal drug price The heads of pharmacy departments in several hospitals said that market transmission itself takes a certain time, so patients can not enjoy the new price in a short period of time Before that, hospitals had stored a certain amount of imported drugs, which were not affected by the price adjustment policy, and the price would be consistent with the previous After the sale of this part of drug inventory, the patients can enjoy dividends.